← Back to Search

Monoclonal Antibodies

OBI-888 for Metastatic Tumor

Phase 1 & 2
Waitlist Available
Led By Apostolia Tsimberidou, MD, PHD
Research Sponsored by OBI Pharma, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 8 weeks (±1 week) for 6 months, then every 12 weeks (±1 week) until progression or off-study criteria, up to 1 year.
Awards & highlights

Study Summary

This study is evaluating whether a drug may help treat cancer.

Eligible Conditions
  • Metastatic Tumor
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 8 weeks (±1 week) for 6 months, then every 12 weeks (±1 week) until progression or off-study criteria, up to 1 year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 8 weeks (±1 week) for 6 months, then every 12 weeks (±1 week) until progression or off-study criteria, up to 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical Benefit Rate (CR, PR, SD) (%)
Secondary outcome measures
Measurement of preliminary clinical activity profile (objective response rate [ORR], clinical benefit rate [CBR], duration of response (DOR), and PFS) of OBI-888 in patients.
Measurement of the OBI-888 immunogenicity (anti-drug antibodies [ADAs]) in patients.
PK - clearance (Cl)
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: OBI-888 Expansion PhaseExperimental Treatment2 Interventions
Part B: Five cohorts at dose level 20 mg/kg of liquid form OBI-888 for intravenous infusion.
Group II: OBI-888 Escalation PhaseExperimental Treatment2 Interventions
Part A: Three cohorts of escalating dose levels of OBI-888 5, 10, and 20 mg/kg liquid form for intravenous infusion to establish maximum tolerated dose (MTD).

Find a Location

Who is running the clinical trial?

OBI Pharma, IncLead Sponsor
7 Previous Clinical Trials
1,324 Total Patients Enrolled
Apostolia Tsimberidou, MD, PHDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
68 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
2018. "This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03573544.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top